HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beiersdorf To Settle Benzene-In-Sunscreen Litigation For $2.3M

Executive Summary

Benzene contamination of Coppertone sunscreen products will cost Beiersdorf $2.3m and require 18 months of benzene testing under a settlement reached with plaintiff Almany Ismael Bangoura, on behalf of himself and consumers nationwide, in New York federal court.

You may also be interested in...



Benzene Suits Against US Personal-Care Firms Appear Headed In One Direction: Settlement

The latest in litigation against Unilever, P&G, Beiersdorf and J&J alleging violations for selling personal-care products contaminated with benzene.

Coppertone Recalls Benzene-Tainted Sunscreens; Cosmetics Regulatory & Legal News

Consumers can contact Coppertone for refunds for aerosol sunscreens found to contain benzene, a human carcinogen that should not adversely affect users at levels detected, the Beiersdorf brand says. More cosmetics regulatory and legal news in brief.

US Interim Funding Bill Gets Biden’s Signature; Window Narrows For Cosmetics, Dietary Supplement Legislation

Passed by the US House and signed into law on 30 September, the Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023, avoids a partial government shutdown and furloughs in FDA user-fee programs. Policy riders stripped from the legislation, including for cosmetics and dietary supplement regulatory changes, could still find their way into a final FY 2023 spending omnibus.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152898

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel